US pharmacies sue J&J for stifling infliximab biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

US pharmacies sue J&J for stifling infliximab biosimilars

Biosimilares/General | Posted 13/07/2018 0 Post your comment

Two major US pharmacy chains, Walgreen and Kroger, have sued healthcare giant Johnson & Johnson (J&J) in the US District Court Eastern District of Pennsylvania. The pharmacies allege that J&J prevented insurers from covering biosimilars of its blockbuster immunology drug Remicade (infliximab).

According to the complaint, Remicade enjoyed monopoly status from 1998 until the entry of Pfizer’s biosimilar, Inflectra (infliximab-dyyb), in 2016 [1] and Merck’s biosimilar, Renflexis (infliximab-abda), in 2017 [2]. This monopoly, according to Walgreen and Kroger, allowed J&J to sell Remicade at extremely high prices and to generate annual US sales of about US$4.8 billion in 2016.

Walgreen and Kroger claim that J&J used exclusionary contracts, bundled discounts and coercive rebates to insurers to maintain a monopoly. This they say suppressed competition from the infliximab biosimilars and meant that they only managed to gain a minimal (‘de minimis’) share (< 5%) of the infliximab market. ‘Absent that exclusionary conduct, those products would have achieved much higher market shares and plaintiffs and other purchasers would have received the benefits of that price competition in the form of lower purchase prices’ the lawsuit claims.

J&J implemented what it described as its ‘Biosimilar Readiness Plan’ within weeks of the approval of Pfizer’s infliximab biosimilar in 2016 [3]. According to the lawsuit this was done to maintain J&J’s market share. The plan included entering into deals with health insurers under which they agreed to exclude infliximab biosimilars from coverage altogether, or to only cover them if treatment with Remicade failed.

These actions have also affected the majority of patients in the US say the two pharmacy chains. They claim that ‘J&J has induced most of the major health insurers in the US, covering at least 70% of privately insured patients in the US, to adopt these exclusionary restrictions’.

References
1. GaBI Online - Generics and Biosimilars Initiative. FDA approves infliximab biosimilar Inflectra [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jul 13]. Available from: www.gabionline.net/Biosimilars/News/FDA-approves-infliximab-biosimilar-Inflectra
2. GaBI Online - Generics and Biosimilars Initiative. FDA approves biosimilar infliximab Renflexis [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jul 13]. Available from: www.gabionline.net/Biosimilars/News/FDA-approves-biosimilar-infliximab-Renflexis
3. GaBI Online - Generics and Biosimilars Initiative. Antitrust activities in the pharmaceutical industry [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jul 13]. Available from: www.gabionline.net/Generics/Research/Antitrust-activities-in-the-pharmaceutical-industry

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Class Action,Knowledge Ecology International